A plasma-based next-generation sequencing option allows for sensitive detection and monitoring of mutations in advanced non-small cell lung cancer. READ MORE
A recent study compared a targeted therapy with standard chemotherapy for treatment-naïve ALK-positive advanced non-small cell lung cancer.
A recent study identified substantial barriers to standard-of-care therapy for limited-stage small cell lung cancer, including government insurance coverage.
Adjuvant EGFR TKI treatment for patients with EGFR-mutant NSCLC after complete resection offers a significant disease-free survival advantage, according to a recent meta-analysis.
Vaccine-based immunotherapy after surgery or radiotherapy did not increase survival in patients with localized non-small-cell lung cancer, according to a recent meta-analysis.